Diasense, a Copenhagen-based quantum startup, has secured €1.3 million ($1.5 million USD) in follow-on funding from the BioInnovation Institute (BII) as part of the Venture House 8 cohort. This capital injection brings the company’s total support from BII to €1.8 million ($2.1 million USD), following its initial seed phase. The funding is specifically earmarked to accelerate the transition of Diasense’s quantum sensing technology from a research-translation stage to a deployable industrial tool for the global semiconductor industry.
The company is industrializing a quantum diamond magnetic microscope designed to provide real-time diagnostics and process insights for next-generation semiconductor fabrication. By utilizing the quantum properties of nitrogen-vacancy (NV) centers in diamond, the platform enables contactless chip failure analysis with microscopic resolution and extreme sensitivity. This technical approach allows manufacturers to uncover complex failure mechanisms and electromagnetic anomalies that remain invisible to traditional scanning electron microscopy or classical induction-based probes.
With this new capital, Diasense will focus on scaling the platform for integration into high-volume manufacturing (HVM) environments. The objective is to provide a fast, non-destructive diagnostic layer that can keep pace with the accelerating complexity of sub-5nm chip architectures. As part of the 1.5-year Venture House program, Diasense will leverage BII’s specialized facilities and strategic network to refine its hardware for the rigorous reliability standards required by tier-one semiconductor foundries.
For further technical details on the Diasense quantum platform and the BII cohort, consult the official announcement via EU-Startups here or visit the Diasense LinkedIn post here.
March 4, 2026
